Cargando…
The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes
Multigene expression assays are prognostic for recurrence in hormone-receptor positive 2 (HER-2) negative breast cancer, and, in some cases, predictive of benefit from chemotherapy or extended endocrine therapy. The results of these assays may be used to guide treatment recommendations for early HER...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366126/ https://www.ncbi.nlm.nih.gov/pubmed/34408795 http://dx.doi.org/10.1177/17588359211038467 |
_version_ | 1783738847836766208 |
---|---|
author | Barbi, Mali Makower, Della Sparano, Joseph A. |
author_facet | Barbi, Mali Makower, Della Sparano, Joseph A. |
author_sort | Barbi, Mali |
collection | PubMed |
description | Multigene expression assays are prognostic for recurrence in hormone-receptor positive 2 (HER-2) negative breast cancer, and, in some cases, predictive of benefit from chemotherapy or extended endocrine therapy. The results of these assays may be used to guide treatment recommendations for early HER-2 negative breast cancer. We review the results of trials establishing the clinical utility of several commercially available gene expression assays. |
format | Online Article Text |
id | pubmed-8366126 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-83661262021-08-17 The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes Barbi, Mali Makower, Della Sparano, Joseph A. Ther Adv Med Oncol Review Multigene expression assays are prognostic for recurrence in hormone-receptor positive 2 (HER-2) negative breast cancer, and, in some cases, predictive of benefit from chemotherapy or extended endocrine therapy. The results of these assays may be used to guide treatment recommendations for early HER-2 negative breast cancer. We review the results of trials establishing the clinical utility of several commercially available gene expression assays. SAGE Publications 2021-08-14 /pmc/articles/PMC8366126/ /pubmed/34408795 http://dx.doi.org/10.1177/17588359211038467 Text en © The Author(s), 2021 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Review Barbi, Mali Makower, Della Sparano, Joseph A. The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes |
title | The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes |
title_full | The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes |
title_fullStr | The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes |
title_full_unstemmed | The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes |
title_short | The clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes |
title_sort | clinical utility of gene expression assays in breast cancer patients with 0–3 involved lymph nodes |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8366126/ https://www.ncbi.nlm.nih.gov/pubmed/34408795 http://dx.doi.org/10.1177/17588359211038467 |
work_keys_str_mv | AT barbimali theclinicalutilityofgeneexpressionassaysinbreastcancerpatientswith03involvedlymphnodes AT makowerdella theclinicalutilityofgeneexpressionassaysinbreastcancerpatientswith03involvedlymphnodes AT sparanojosepha theclinicalutilityofgeneexpressionassaysinbreastcancerpatientswith03involvedlymphnodes AT barbimali clinicalutilityofgeneexpressionassaysinbreastcancerpatientswith03involvedlymphnodes AT makowerdella clinicalutilityofgeneexpressionassaysinbreastcancerpatientswith03involvedlymphnodes AT sparanojosepha clinicalutilityofgeneexpressionassaysinbreastcancerpatientswith03involvedlymphnodes |